Header Logo

Connection

Raid Aljumaily to Antibodies, Bispecific

Back to Details
This is a "connection" page, showing publications Raid Aljumaily has written about Antibodies, Bispecific.
Raid Aljumaily
Connection Strength
0.158
Antibodies, Bispecific
  1. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
    View in: PubMed
    Score: 0.158
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.